SMART 102
Alternative Names: SMART-102Latest Information Update: 02 Aug 2022
At a glance
- Originator Smart Immune
- Developer Assistance Publique - Hopitaux de Marseille
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 31 Oct 2021 Phase-I/II clinical trials in Acute myeloid leukaemia (In adults, In the elderly) in France (IV) (NCT04707300)
- 31 Oct 2021 Phase-I/II clinical trials in Myelodysplastic syndromes (In adults, In the elderly) in France (IV) (NCT04707300)